stockrow
Sunday 15 November 2026
Export TAK’s income statement to Excel — free account
Takeda Pharmaceutical Co.
TAKHealthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
21.43
0.31
+1.47%
Follow TAK
Alert me
| Sep '26 | Jun '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 24.12 | — | — |
+8 more quarters Free account |
P/S ratio |
— | 1.69 | — | — | |
P/FCF ratio |
— | 6.83 | — | — | |
P/Operating CF |
— | 63.00 | — | — | |
P/B ratio |
— | 1.06 | — | — | |
Price to Tangible BV |
— | 0.00 | — | — | |
EV/Sales |
— | 2.62 | — | — | |
EV/EBITDA |
— | 9.41 | — | — | |
EV/Operating CF |
— | 7.05 | — | — | |
EV/FCF |
— | 10.57 | — | — | |
Quick Ratio |
0.52 | 0.54 | 0.58 | 0.67 | |
Current Ratio |
1.15 | 1.14 | 1.19 | 1.37 | |
Net Debt/EBITDA |
0.00 | 12.11 | 0.00 | 0.00 | |
Debt/Assets |
29.96% | 31.54% | 31.50% | 32.10% | |
Debt/Equity |
0.62 | 0.65 | 0.63 | 0.65 | |
Asset Turnover |
0.00 | 0.30 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 1.13 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.34) | (0.63) | (0.62) | (0.28) | |
Interest Coverage |
— | 3.15 | — | — | |
Research and Development Expense of Revenue |
— | 13.72% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 23.49% | — | — | |
Intangible Assets out of Total Assets |
0.58 | 0.59 | 0.60 | 0.60 | |
Share Based Compensation of Revenue |
0.00% | 1.49% | 0.00% | 0.00% | |
Graham Net Nets |
— | (0.62) | — | — | |
Graham Number |
— | 15.01 | — | — | |
Earnings Yield |
— | 4.15% | — | — | |
Free Cash Flow Yield |
— | 14.65% | — | — | |
Revenue per Share |
— | 2.43 | — | — | |
Operating CF per Share |
0.00 | 0.25 | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.20) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.05 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 1.05 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 15.07 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 15.07 | 0.00 | 0.00 | |
Free Cash Flow |
1,568.12 | 160.54 | 4,049.74 | 2,198.07 | |
Working Capital |
2,479.72 | 2,430.05 | 3,290.66 | 5,310.57 | |
Capital Expenditures |
(348.76) | (643.48) | (2,235.13) | (352.34) | |
Net Current Asset Value |
(30,600.15) | (31,210.98) | (30,213.59) | (30,042.33) | |
EV/EBIT |
— | 22.54 | — | — | |
Capex to Sales |
0.00 | 0.08 | 0.00 | 0.00 | |
Price to Operating Income |
— | 14.55 | — | — | |
| Other line items | |||||
Average Receivables |
5,211.65 | 5,437.55 | 4,878.78 | 4,859.18 | |
Average Payables |
2,985.03 | 2,925.97 | 2,904.35 | 2,992.97 | |
Average Inventory |
8,819.76 | 8,672.07 | 8,614.92 | 8,503.82 | |
Average Assets |
96,420.87 | 99,191.89 | 98,898.05 | 101,127.62 | |
Average Common Equity |
47,052.43 | 48,293.79 | 48,030.65 | 49,205.30 |
Columns are period end dates · fundamentals updated 2 Nov 2026